Speech-Language Pathologists in Orange, CA Accepting Medicare
125 Speech-Language Pathologists found. Showing 121 - 125
 Madison Dano Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 393 S Tustin St, Orange, CA 92866 Phone: 714-289-2400 |
Ms. Sheila M Fry, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1301 W Providence Ave, Orange, CA 92868 Phone: 855-901-7742 |
 Jonathan Forfa Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 208 W Mayfair Ave, Orange, CA 92867 Phone: 413-427-5250 |
Ms. Cathie Strand, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1301 W Providence Ave, Orange, CA 92868 Phone: 714-328-6697 |
Vanessa Kang, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-6237 |
News Archive
Healthcare thought leaders and experts to meet in MCEG 2010 Annual Forum
The Managed Care Executive Group has gathered some of healthcare's most distinguished thought leaders and experts on healthcare reform to meet March 21-24 in Fort Lauderdale Florida for their Annual Forum entitled "Reform + Evolution = Revolution".
Liquidia commences dosing in LIQ-001 Phase 1 trial for seasonal influenza
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
World's first vaccine against coeliac disease to be tested in Australia
US-based pharmaceutical company ImmusanT, after worldwide trials, is all set to start clinical trials of a new vaccine against coeliac disease at the Royal Melbourne Hospital Clinical Trials Centre in Melbourne. This will be followed by trials to be held at Adelaide, Brisbane, Perth, Mackay and Sunshine Coast say the sources.
Study suggests new targets for treating rare genetic disorder and cancer
The combined action of two enzymes, Srs2 and Exo1, prevents and repairs common genetic mutations in growing yeast cells, according to a new study led by scientists at NYU Langone Medical Center.
New method for examining how radiation damages body tissue
The knowledge may make it possible to reduce side effects for cancer patients or to develop treatments for radiation exposure.
› Verified 6 days ago
Physical Therapists
Speech-Language Pathologists
Chiropractors
Occupational Therapists
Optometrists
Audiologists
Podiatrists